AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)
NCT07158905
This study is recruiting at 6 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a Phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple-dose-escalation study evaluating the safety, tolerability, and immunogenicity of AV-1980R, an investigational vaccine targeting pathological tau, in participants with preclinical Alzheimer's disease. Up to 48 cognitively unimpaired adults aged 65 to 80 years with biomarker evidence of preclinical Alzheimer's disease will be enrolled into three ascending-dose cohorts.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Alzheimer Disease
- Preclinical Alzheimer's Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 65 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Institute for Molecular Medicine
- Last updated on ClinicalTrials.gov
- August 21, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 5
- Comprehensive Center for Brain Health · Boca Raton, FL
- Palm Springs Community Health Center · Miami Lakes, FL
- Alzheimer's Research and Treatment Center (Stuart) · Stuart, FL
- University of South Florida · Tampa, FL
- Alzheimer's Research and Treatment Center (Wellington) · Wellington, FL
Georgia · 1
- Alzheimer's Research and Treatment Center (Columbus) · Columbus, GA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.